Medifast price target lowered to $12 from $15 at Stephens

Stephens lowered the firm’s price target on Medifast (MED) to $12 from $15 and keeps an Equal Weight rating on the shares. While the firm believes that operating discipline and restructuring savings are important, the “key proof point will be a return to growth in the coach count,” the analyst tells investors in a post-earnings note.